Zions Bancorporation, National Association’s Fulcrum Therapeutics FULC Stock Holding History

Zions Bancorporation, National Association’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$355	Buy	+97	New	+$590	﹤0.01%	1578

Other funds holding FULC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Zions Bancorporation, National Association's FULC Position: Q2 2026 in Review

Zions Bancorporation, National Association opened a new position in Fulcrum Therapeutics (FULC) in Q2 2026: 97 shares worth $355. The stake represents ﹤0.01% of the portfolio and ranks #1578 among its holdings.

155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

Zions Bancorporation, National Association held 97 shares of Fulcrum Therapeutics worth $355 as of Q2 2026.
Fulcrum Therapeutics was a new Zions Bancorporation, National Association position in Q2 2026.
Fulcrum Therapeutics made up ﹤0.01% of Zions Bancorporation, National Association's portfolio in Q2 2026, its #1578 holding.
155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Zions Bancorporation, National Association's 13F filing for Q2 2026, filed 31 Jul 2026.